Aug 16 (Reuters) - Endo International Plc filed for
bankruptcy on Tuesday after reaching a $6 billion deal with some
of its creditors, as the U.S. drugmaker seeks to settle
thousands of lawsuits over its alleged role in the country's
The pharmaceutical company is the latest to file for Chapter
11 to address opioid claims. Purdue Pharma, the maker of
OxyContin, filed in September 2019, while Mallinckrodt Plc, a
generic opioid manufacturer, recently emerged from bankruptcy.
"By definitively addressing the more than $8 billion of debt
that has burdened our balance sheet and establishing a pathway
to closure with respect to the thousands of opioid-related and
other lawsuits that the company has been defending at an
unsustainable cost, we will be able to move forward...," Endo's
Chief Executive Officer Blaise Coleman said in a statement.
The company's Chapter 11 bankruptcy filing in the Southern
District of New York showed assets and liabilities in the range
of $1 billion to $10 billion.
The creditors, who will also assume some of the company's
liabilities, will substantially control all of its assets, Endo
The company also reached a deal with U.S. state attorneys
general to provide $450 million over a period of 10 years,
resolving allegations that the company boosted opioid sales
using deceptive marketing, and bans the marketing of its opioids
forever, according to the office of Massachusetts AG.
Creditors will also establish voluntary trusts with $550
million to be funded over 10 years to settle the opioid claims,
the company said.
Endo has been discussing the possibility of filing for
bankruptcy protection in several recent filings.
In June, the drugmaker missed a $38 million interest
payment, amid discussions with a group of unsecured bondholders
who had urged the company to avoid filing for bankruptcy.
(Reporting by Jahnavi Nidumolu and Shubham Kalia in Bengaluru;
Editing by Neha Arora, Rashmi Aich and Sriraj Kalluvila)